DOCSLIB.ORG

TLR9 Gene Transcriptional Regulation of the Human

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
TLR9 Gene Transcriptional Regulation of the Human Transcriptional Regulation of the Human TLR9 Gene Fumihiko Takeshita, Koichi Suzuki, Shin Sasaki, Norihisa Ishii, Dennis M. Klinman and Ken J. Ishii This information is current as of September 30, 2021. J Immunol 2004; 173:2552-2561; ; doi: 10.4049/jimmunol.173.4.2552 http://www.jimmunol.org/content/173/4/2552 Downloaded from References This article cites 49 articles, 31 of which you can access for free at: http://www.jimmunol.org/content/173/4/2552.full#ref-list-1 Why The JI? Submit online. http://www.jimmunol.org/ • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average by guest on September 30, 2021 Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2004 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Transcriptional Regulation of the Human TLR9 Gene1 Fumihiko Takeshita,2* Koichi Suzuki,† Shin Sasaki,‡ Norihisa Ishii,‡ Dennis M. Klinman,* and Ken J. Ishii3* To clarify the molecular basis of human TLR9 (hTLR9) gene expression, the activity of the hTLR9 gene promoter was charac- terized using the human myeloma cell line RPMI 8226. Reporter gene analysis and EMSA demonstrated that hTLR9 gene transcription was regulated via four cis-acting elements, cAMP response element, 5؅-PU box, 3؅-PU box, and a C/EBP site, that interacted with the CREB1, Ets2, Elf1, Elk1, and C/EBP␣ transcription factors. Other members of the C/EBP family, such as C/EBP␤, C/EBP␦, and C/EBP⑀, were also important for TLR9 gene transcription. CpG DNA-mediated suppression of TLR9 gene transcription led to decreased binding of the trans-acting factors to their corresponding cis-acting elements. It appeared that suppression was mediated via c-Jun and NF-␬B p65 and that cooperation among CREB1, Ets2, Elf1, Elk1, and C/EBP␣ culmi- nated in maximal transcription of the TLR9 gene. These findings will help to elucidate the mechanism of TLR9 gene regulation and to provide insight into the process by which TLR9 evolved in the mammalian immune system. The Journal of Immunology, 2004, Downloaded from 173: 2552–2561. he mammalian innate immune system has evolved to ex- flammatory cytokines (IL-1, IL-6, IL-12, IL-18, and TNF-␣), and press TLRs able to sense pathogen-associated molecular chemokines (MIP-1␣, MIP-1␤, MIP-2, RANTES, JE/MCP-1, and patterns, enabling early responses against pathogens. Of IP-10) (9–12). T http://www.jimmunol.org/ the 10 TLRs so far discovered, TLR9 is thought to recognize the The signal transduction pathway mediated by the interaction specific conformation of CpG DNA, thereby mediating signaling between CpG DNA and TLR9 is shared with the other functionally pathways that direct innate immune activation (1, 2). CpG motifs, characterized members of the TLR family and involves the my- consisting of unmethylated CpG dinucleotides flanked by two 5Ј eloid differentiation marker 88, IL-1R-associated kinase, TNFR- purines and two 3Ј pyrimidines, are more common in bacterial associated factor 6, TGF␤-activated kinase1, and I␬B kinases, DNA than in vertebrate DNA, which suggests that TLR9 plays an I␬B, and NF-␬B (13). Recent studies have demonstrated that the important role in discriminating between bacterial and self DNA formation and maturation of CpG DNA-containing endosomes are (3). CpG oligodeoxynucleotides (ODNs)4 have been demonstrated regulated by PI3Ks and the ras-associated GTP-binding protein to have clinically promising properties in a number of areas, in- Rab5 and are essential for the initiation of TLR9-mediated signal- cluding stimulation of innate immunity to combat pathogens and ing (14, 15). Suppressive ODNs compete with CpG DNA for bind- by guest on September 30, 2021 cancer cells, enhanced vaccine antigenicity via acquired immunity, ing to TLR9, which results in blocking of this signaling pathway and immune modulation toward Th1-dominant responses that can (7). Chloroquine (CQ) also blocks CpG DNA-mediated signaling suppress allergic responses (4–8). Recent studies have shown that by down-regulating the maturation of CpG DNA-containing a subset of CpG ODN, termed D-type CpG ODN (or CpG-A) can endosomes (8). directly activate plasmacytoid dendritic cells (PDCs) and NK cells Mouse TLR9 (mTLR9) mRNA is abundantly expressed in the to produce IFN-␣␤ and IFN-␥, respectively. Another CpG ODN spleen. Of the various cell types, PDCs show the strongest TLR9 subset, termed K-type CpG ODN (or CpG-B), preferentially stim- gene expression (16, 17). Although expression is weak in B cells ulates B cells, monocytes, and macrophages to produce Ig, proin- and monocytes, augmented TLR9 expression in response to anti-Ig cross-linking or IFN-␥ stimulation correlates with increased re- sponsiveness to CpG DNA (18, 19). Of the commercially available *Section of Retroviral Immunology, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892; †Laboratory of Molecular En- cell lines, the human myeloma cell line RPMI 8226 expresses suf- docrinology, Medstar Research Institute, Washington Hospital Center, Washington, ficient TLR9 to respond to CpG DNA. K-type CpG ODN, but not DC 20010; and ‡Department of Bioregulation, National Institute of Infectious Dis- eases, Tokyo, Japan D-type CpG ODN, activates RPMI 8226 to produce IL-6, IL-12 p40, MIP-1␣, MIP-1␤, and RANTES (11, 20, 21). To examine the Received for publication December 29, 2003. Accepted for publication June 1, 2004. cis-acting elements essential for constitutive activation of the hu- The costs of publication of this article were defrayed in part by the payment of page Ј charges. This article must therefore be hereby marked advertisement in accordance man TLR9 (hTLR9) gene promoter in RPMI 8226, the 5 -flanking with 18 U.S.C. Section 1734 solely to indicate this fact. region of the hTLR9 gene was cloned and characterized. Our re- 1 This work was supported in part by the Yokohama Medical Foundation. sults identified four cis-acting elements and demonstrated the bind- 2 Address correspondence and reprint requests to Dr. Fumihiko Takeshita at the cur- ing of various CREB, Ets, and C/EBP transcription factors. rent address: Department of Molecular Biodefense Research, Yokohama City Uni- versity School of Medicine, 3-9 Fukuura, Kanazawaku, Yokohama 236-0004, Japan. E-mail address: [email protected] 3 Current address: Exploratory Research for Advanced Technology (Japan), Japan Materials and Methods Science and Technology Agency, Department of Host Defense, Research Institute for Reagents Microbial Diseases, Osaka University, 3-1 Yamada-oka, Suita, Osaka 565-0871, Japan. ODNs were synthesized (Center for Biologics, Evaluation, and Research 4 Abbreviations used in this paper: ODN, oligodeoxynucleotide; PDC, plasmacytoid core facility, Bethesda, MD) according to the following sequences: K3, dendritic cell; CQ, chloroquine; m, mouse; h, human; ATF, activating transcription ATC GAC TCT CGA GCG TTC TC; K3 flip, ATG CAC TCT GCA GG factor; CRE, cAMP response element; MDC, myeloid dendritic cell; IRF, IFN reg- C TTC TC (2); D19, GGt gca tcg atg caG GGG G (9); H154, CCT CAA ulatory factor. GCT TGA GGG G (22); A151, TTA GGG TTA GGG TTA GGG TTA Copyright © 2004 by The American Association of Immunologists, Inc. 0022-1767/04/$02.00 The Journal of Immunology 2553 GGG (23); and 1471, TCA AGC TTG A (uppercase letters indicate phos- The sequence of each PCR product was confirmed using an ABI PRISM phorothioates and lowercase letters indicate phosphodiesters). LPS, IFN-␥, Genetic Analyzer (PE Applied Biosystems, Foster City, CA). and CQ were purchased from Sigma-Aldrich (St. Louis, MO). Anti- CREB1, -activating transcription factor 2 (ATF2), -Ets1/2, -Ets2, -Elf1, Construction of transcription factor expression vectors ␣ ␤ ␥ ␦ ⑀ -Elk1, -Spi1 (PU.1), -C/EBP , -C/EBP , -C/EBP , -C/EBP , -C/EBP , Human cDNAs encoding Ets1, Ets2, Elf1, Elk1, Spi1 (PU.1), SpiB, SpiC, and -Sp1 Abs were from Santa Cruz Biotechnology (Santa Cruz, CA). CREB1, ATF2, C/EBP␣, C/EBP␤, C/EBP␥, C/EBP␦, and C/EBP⑀ were amplified by PCR using a Marathon-Ready cDNA library derived from Cell lines and cell cultures human spleen (BD Clontech, Palo Alto, CA) and primers as shown in ␬ RPMI 8226 and THP-1 cells were purchased from American Type Culture Table I. Mouse cDNA encoding c-Fos, c-Jun, or NF- B p65 were also PCR Collection (Manassas, VA). Cells were grown in RPMI 1640 (Sigma-Aldrich) amplified from the mouse spleen cDNA library using primers shown in supplemented with 10% FBS, 50 ␮g/ml penicillin/streptomycin, and 0.1 mM Table I. All PCR products were gel-purified and cloned into the mamma- nonessential amino acids. Cells were maintained at 37°Cin5%CO. lian expression vector pCIneo (Promega). Sequences of the PCR products 2 were confirmed using an ABI PRISM Genetic Analyzer (PE Applied RT-PCR Biosystems). Semiquantitative RT-PCR was performed as previously described (21). 5Ј-RACE Briefly, total RNA was extracted with TRIzol reagent (Invitrogen, Carls- 5Ј-RACE was performed on hTLR9 cDNA using a SMART RACE cDNA bad, CA) according to the manufacturer’s protocol, and 5 ␮ g of total RNA Amplification Kit (BD Clontech). A 36-cycle touch-down PCR, in which was reverse transcribed in first strand buffer (50 mM Tris-HCl (pH 7.5), 75 the annealing temperature was reduced 2°C every 12 cycles from 70°C, mM KCl, and 2.5 mM MgCl ) containing 25 ng/␮l oligo(dT) , 200 U 2 12–18 was performed using the AP-1 primer (BD Clontech), the ϩ365/TLR9 AS of Moloney leukemia virus reverse transcriptase, 2 mM dNTP, and 10 mM primer, 5Ј-ACA GCC AAG AAG GTG CTG GGC TCG ATGG-3Ј, and the DTT.
Load more

Recommended publications
  • TLR4 and TLR9 Ligands Macrophages Induces Cross
    Lymphotoxin β Receptor Activation on Macrophages Induces Cross-Tolerance to TLR4 and TLR9 Ligands This information is current as Nadin Wimmer, Barbara Huber, Nicola Barabas, Johann of September 27, 2021. Röhrl, Klaus Pfeffer and Thomas Hehlgans J Immunol 2012; 188:3426-3433; Prepublished online 22 February 2012; doi: 10.4049/jimmunol.1103324 http://www.jimmunol.org/content/188/7/3426 Downloaded from Supplementary http://www.jimmunol.org/content/suppl/2012/02/23/jimmunol.110332 Material 4.DC1 http://www.jimmunol.org/ References This article cites 42 articles, 13 of which you can access for free at: http://www.jimmunol.org/content/188/7/3426.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision by guest on September 27, 2021 • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2012 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Lymphotoxin b Receptor Activation on Macrophages Induces Cross-Tolerance to TLR4 and TLR9 Ligands Nadin Wimmer,* Barbara Huber,* Nicola Barabas,* Johann Ro¨hrl,* Klaus Pfeffer,† and Thomas Hehlgans* Our previous studies indicated that lymphotoxin b receptor (LTbR) activation controls and downregulates inflammatory reac- tions.
    [Show full text]
  • B Cells Expression in Follicular and Marginal Zone TLR Stimulation
    TLR Stimulation Modifies BLyS Receptor Expression in Follicular and Marginal Zone B Cells This information is current as Laura S. Treml, Gianluca Carlesso, Kristen L. Hoek, Jason of October 2, 2021. E. Stadanlick, Taku Kambayashi, Richard J. Bram, Michael P. Cancro and Wasif N. Khan J Immunol 2007; 178:7531-7539; ; doi: 10.4049/jimmunol.178.12.7531 http://www.jimmunol.org/content/178/12/7531 Downloaded from References This article cites 57 articles, 25 of which you can access for free at: http://www.jimmunol.org/content/178/12/7531.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on October 2, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2007 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology TLR Stimulation Modifies BLyS Receptor Expression in Follicular and Marginal Zone B Cells1 Laura S. Treml,2* Gianluca Carlesso,2† Kristen L. Hoek,† Jason E. Stadanlick,* Taku Kambayashi,* Richard J.
    [Show full text]
  • Genetic Variation of the Toll-Like Receptors in a Swedish Allergic Rhinitis Case Population
    http://www.diva-portal.org This is the published version of a paper published in BMC Medical Genetics. Citation for the original published paper (version of record): Henmyr, V., Carlberg, D., Manderstedt, E., Lind-Halldén, C., Säll, T. et al. (2017) Genetic variation of the toll-like receptors in a Swedish allergic rhinitis case population. BMC Medical Genetics, 18(1): 18 https://doi.org/10.1186/s12881-017-0379-6 Access to the published version may require subscription. N.B. When citing this work, cite the original published paper. Permanent link to this version: http://urn.kb.se/resolve?urn=urn:nbn:se:hkr:diva-16592 Henmyr et al. BMC Medical Genetics (2017) 18:18 DOI 10.1186/s12881-017-0379-6 RESEARCHARTICLE Open Access Genetic variation of the Toll-like receptors in a Swedish allergic rhinitis case population V. Henmyr1,2*†, D. Carlberg2†, E. Manderstedt1,2, C. Lind-Halldén2, T. Säll1, L. O. Cardell3 and C. Halldén2 Abstract Background: Variation in the 10 toll-like receptor (TLR) genes has been significantly associated with allergic rhinitis (AR) in several candidate gene studies and three large genome-wide association studies. These have all investigated common variants, but no investigations for rare variants (MAF ≤ 1%) have been made in AR. The present study aims to describe the genetic variation of the promoter and coding sequences of the 10 TLR genes in 288 AR patients. Methods: Sanger sequencing and Ion Torrent next-generation sequencing was used to identify polymorphisms in a Swedish AR population and these were subsequently compared and evaluated using 1000Genomes and Exome Aggregation Consortium (ExAC) data.
    [Show full text]
  • Combined Carriership of TLR9 -1237C and CD14 -260T Alleles Enhances the Risk of Developing Chronic Relapsing Pouchitis
    CORE Metadata, citation and similar papers at core.ac.uk Provided by DSpace at VU PO Box 2345, Beijing 100023, China World J Gastroenterol 2005;11(46):7323-7329 www.wjgnet.com World Journal of Gastroenterology ISSN 1007-9327 [email protected] © 2005 The WJG Press and Elsevier Inc. All rights reserved. ELSEVIER • RAPID COMMUNICATION • Combined carriership of TLR9 -1237C and CD14 -260T alleles enhances the risk of developing chronic relapsing pouchitis KM Lammers, S Ouburg, SA Morré, JBA Crusius, P Gionchetti, F Rizzello, C Morselli, E Caramelli, R Conte, G Poggioli, M Campieri, AS Peña KM Lammers, P Gionchetti, F Rizzello, C Morselli, M CONCLUSION: There is no evidence that the SNPs Campieri, Department of Internal Medicine and Gastroenterology, predispose to the need for IPAA surgery. The signifi cant Policlinico S. Orsola, University of Bologna, Bologna, Italy increase of the combined carriership of the CD14 S Ouburg, SA Morré, JBA Crusius, AS Peña, Laboratory of -260T and TLR9 -1237C alleles in the chronic relapsing Immunogenetics, VU University Medical Center, Amsterdam, The pouchitis group suggests that these markers identify Netherlands a subgroup of IPAA patients with a risk of developing E Caramelli, Institute of Histology and General Embryology, University of Bologna, Bologna, Italy chronic or refractory pouchitis. R Conte, Department of Immunohaematology and Blood Transfusion, Policlinico S. Orsola, University of Bologna, © 2005 The WJG Press and Elsevier Inc. All rights reserved. Bologna, Italy AS Peña, Laboratory of Immunogenetics and Department of Key words: Pouchitis; Innate immunity; Single nucleotide Gastroenterology, VU University Medical Center, Amsterdam, polymorphisms; CD14 ; TLR9 The Netherlands G Poggioli, Department of Surgery and Organ Transplantation, Lammers KM, Ouburg S, Morré SA, Crusius JBA, Gionchetti Policlinic S.
    [Show full text]
  • Toll-Like Receptors and Relevant Emerging Therapeutics with Reference to Delivery Methods
    pharmaceutics Review Toll-Like Receptors and Relevant Emerging Therapeutics with Reference to Delivery Methods Nasir Javaid, Farzana Yasmeen and Sangdun Choi * Department of Molecular Science and Technology, Ajou University, Suwon 16499, Korea * Correspondence: [email protected]; Tel.: +82-31-219-2600 Received: 9 July 2019; Accepted: 28 August 2019; Published: 1 September 2019 Abstract: The built-in innate immunity in the human body combats various diseases and their causative agents. One of the components of this system is Toll-like receptors (TLRs), which recognize structurally conserved molecules derived from microbes and/or endogenous molecules. Nonetheless, under certain conditions, these TLRs become hypofunctional or hyperfunctional, thus leading to a disease-like condition because their normal activity is compromised. In this regard, various small-molecule drugs and recombinant therapeutic proteins have been developed to treat the relevant diseases, such as rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, systemic lupus erythematosus, and allergy. Some drugs for these diseases have been clinically approved; however, their efficacy can be enhanced by conventional or targeted drug delivery systems. Certain delivery vehicles such as liposomes, hydrogels, nanoparticles, dendrimers, or cyclodextrins can be employed to enhance the targeted drug delivery. This review summarizes the TLR signaling pathway, associated diseases and their treatments, and the ways to efficiently deliver the drugs to a target site. Keywords: Toll-like receptor; immunological disease; therapeutic; drug delivery method 1. Introduction The immune system in an organism is the protective system combating pathogenic and/or abnormal conditions. Innate and adaptive immune systems are two basic components in vertebrates. Adaptive immunity is mediated by T and B lymphocytes with the help of their antigen-specific receptors that are encoded as a result of hypermutability and rearrangements in a genomic region of the organism.
    [Show full text]
  • Not Signaling Mechanisms of Innate Immune Sensing but Human Tlrs
    Human TLRs 10 and 1 Share Common Mechanisms of Innate Immune Sensing but Not Signaling This information is current as Yue Guan, Diana Rose E. Ranoa, Song Jiang, Sarita K. of September 26, 2021. Mutha, Xinyan Li, Jerome Baudry and Richard I. Tapping J Immunol 2010; 184:5094-5103; Prepublished online 26 March 2010; doi: 10.4049/jimmunol.0901888 http://www.jimmunol.org/content/184/9/5094 Downloaded from Supplementary http://www.jimmunol.org/content/suppl/2010/03/25/jimmunol.090188 Material 8.DC1 http://www.jimmunol.org/ References This article cites 74 articles, 29 of which you can access for free at: http://www.jimmunol.org/content/184/9/5094.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision by guest on September 26, 2021 • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2010 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Human TLRs 10 and 1 Share Common Mechanisms of Innate Immune Sensing but Not Signaling Yue Guan,* Diana Rose E.
    [Show full text]
  • Human TLR1-9 Agonist Kit Set of Known Agonists for Human TLR1 to TLR9 Catalog Code: Tlrl-Kit1hw
    Human TLR1-9 Agonist Kit Set of known agonists for human TLR1 to TLR9 Catalog code: tlrl-kit1hw https://www.invivogen.com/human-tlr1-9-agonist-kit For research use only Version 19B14-MM PRODUCT INFORMATION • Poly(I:C) HMW and Poly(I:C) LMW - TLR3 agonists Contents Poly(I:C) is a synthetic analog of double-stranded RNA (dsRNA), • TLR1/2 agonist - Pam3CSK4 (10 µg) a molecular pattern associated with viral infection. Poly(I:C) is • TLR2 agonist - HKLM (109 cells) composed of a strand of poly(I) annealed to a strand of poly(C). • TLR3 agonist - Poly(I:C) HMW (500 µg) The size of the strands varies. Poly(I:C) HMW has a high • TLR3 agonist - Poly(I:C) LMW (500 µg) molecular weight (average size 1.5-8 kb), whereas Poly(I:C) • TLR4 agonist - LPS-EK standard (100 µg) LMW has a low molecular weight (average size 0.2-1 kb). • TLR5 agonist - FLA-ST standard(10 µg) Poly(I:C) HMW and Poly(I:C) LMW may activate the immune • TLR6/2 agonist - FSL-1 (10 µg) system differently. dsRNA is known to induce interferons (IFNs) • TLR7 agonist - Imiquimod (25 µg) and other cytokines production. IFN induction is mediated by • TLR8 agonist - ssRNA40 (25 µg) two different pathways. The first pathway leading to NF-κB • TLR9 agonist - ODN2006 (100 µg - 12.98 nmol) activation depends on the dsRNA-responsive protein kinase • 2 x 2 ml endotoxin-free water (PKR)5, whereas the second pathway is PKR-independent and involves TLR36. Storage and stability - Products are shipped at room temperature and should be stored • LPS from E.
    [Show full text]
  • Imidazoquinolines Modulate Activation of TLR7 and TLR8 By
    Oligodeoxynucleotides Differentially Modulate Activation of TLR7 and TLR8 by Imidazoquinolines This information is current as Keith K. B. Gorden, Xiaohong Qiu, John J. L. Battiste, Paul of September 28, 2021. P. D. Wightman, John P. Vasilakos and Sefik S. Alkan J Immunol 2006; 177:8164-8170; ; doi: 10.4049/jimmunol.177.11.8164 http://www.jimmunol.org/content/177/11/8164 Downloaded from References This article cites 34 articles, 14 of which you can access for free at: http://www.jimmunol.org/content/177/11/8164.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 28, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2006 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Oligodeoxynucleotides Differentially Modulate Activation of TLR7 and TLR8 by Imidazoquinolines Keith K. B. Gorden, Xiaohong Qiu, John J. L. Battiste, Paul P. D. Wightman, John P. Vasilakos, and Sefik S. Alkan1 Among the 11 human TLRs, a subfamily TLR7, TLR8, and TLR9 display similarities in structure and endosomal localization.
    [Show full text]
  • Human TLR9 Confers Responsiveness to Bacterial DNA Via Species-Specific Cpg Motif Recognition
    Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition Stefan Bauer*†‡, Carsten J. Kirschning*†, Hans Ha¨ cker*, Vanessa Redecke*, Susanne Hausmann*, Shizuo Akira§, Hermann Wagner*, and Grayson B. Lipford*‡ *Institute for Medical Microbiology, Immunology and Hygiene, Technical University of Munich, 81675 Munich, Germany; and §Department of Host Defense, Research Institute for Microbial Diseases, Osaka University, Osaka 565-0871, Japan Communicated by Johannes van Rood, Europdonor Foundation, Leiden, The Netherlands, June 11, 2001 (received for review February 2, 2001) The Toll-like receptor (TLR) family consists of phylogenetically human TLR9 (hTLR9) is correlated with CpG-DNA respon- conserved transmembrane proteins, which function as mediators siveness in primary human cells and that transfection of either of innate immunity for recognition of pathogen-derived ligands hTLR9 or mTLR9 into nonresponsive cells reconstitutes and subsequent cell activation via the Toll͞IL-1R signal pathway. MyD88-dependent CpG-DNA responses. Transfected hTLR9 Here, we show that human TLR9 (hTLR9) expression in human and mTLR9 required distinct CpG motifs for signal initiation, immune cells correlates with responsiveness to bacterial deoxy- implying they directly engage immunostimulatory CpG-DNA in cytidylate-phosphate-deoxyguanylate (CpG)-DNA. Notably ‘‘gain a species-specific manner. of function’’ to immunostimulatory CpG-DNA is achieved by ex- pressing TLR9 in human nonresponder cells. Transfection of either Materials and Methods human or murine TLR9 conferred responsiveness in a CD14- and Cells and Reagents. Human embryonic kidney 293 cells were from MD2-independent manner, yet required species-specific CpG-DNA ATCC. Peripheral blood mononuclear cells (PBMC), human B ϩ motifs for initiation of the Toll͞IL-1R signal pathway via MyD88.
    [Show full text]
  • TLR10 Is a B Cell Intrinsic Suppressor of Adaptive Immune Responses Nicholas J
    TLR10 Is a B Cell Intrinsic Suppressor of Adaptive Immune Responses Nicholas J. Hess, Song Jiang, Xinyan Li, Yue Guan and Richard I. Tapping This information is current as of September 23, 2021. J Immunol published online 12 December 2016 http://www.jimmunol.org/content/early/2016/12/09/jimmun ol.1601335 Downloaded from Supplementary http://www.jimmunol.org/content/suppl/2016/12/09/jimmunol.160133 Material 5.DCSupplemental Why The JI? Submit online. http://www.jimmunol.org/ • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average by guest on September 23, 2021 Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2016 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Published December 12, 2016, doi:10.4049/jimmunol.1601335 The Journal of Immunology TLR10 Is a B Cell Intrinsic Suppressor of Adaptive Immune Responses Nicholas J. Hess,*,1 Song Jiang,*,†,1 Xinyan Li,* Yue Guan,* and Richard I. Tapping*,† Toll-like receptors play a central role in the initiation of adaptive immune responses with several TLR agonists acting as known B cell mitogens.
    [Show full text]
  • Recognition of Lipopolysaccharide Pattern by TLR4 Complexes
    OPEN Experimental & Molecular Medicine (2013) 45, e66; doi:10.1038/emm.2013.97 & 2013 KSBMB. All rights reserved 2092-6413/13 www.nature.com/emm REVIEW Recognition of lipopolysaccharide pattern by TLR4 complexes Beom Seok Park1 and Jie-Oh Lee2 Lipopolysaccharide (LPS) is a major component of the outer membrane of Gram-negative bacteria. Minute amounts of LPS released from infecting pathogens can initiate potent innate immune responses that prime the immune system against further infection. However, when the LPS response is not properly controlled it can lead to fatal septic shock syndrome. The common structural pattern of LPS in diverse bacterial species is recognized by a cascade of LPS receptors and accessory proteins, LPS binding protein (LBP), CD14 and the Toll-like receptor4 (TLR4)–MD-2 complex. The structures of these proteins account for how our immune system differentiates LPS molecules from structurally similar host molecules. They also provide insights useful for discovery of anti-sepsis drugs. In this review, we summarize these structures and describe the structural basis of LPS recognition by LPS receptors and accessory proteins. Experimental & Molecular Medicine (2013) 45, e66; doi:10.1038/emm.2013.97; published online 6 December 2013 Keywords: lipopolysaccharide (LPS); Toll-like receptor 4 (TLR4); MD-2; CD14; LBP INTRODUCTION the cell surface by a glycosylphosphatidylinositol anchor. CD14 In the initial phase of infection, the innate immune system splits LPS aggregates into monomeric molecules and presents generates a rapid inflammatory response that blocks the them to the TLR4–MD-2 complex. Aggregation of the TLR4– growth and dissemination of the infectious agent.
    [Show full text]
  • TLR8 Differences Between Human TLR7 and Synthetic TLR Agonists
    Synthetic TLR Agonists Reveal Functional Differences between Human TLR7 and TLR8 Keith B. Gorden, Kevin S. Gorski, Sheila J. Gibson, Ross M. Kedl, William C. Kieper, Xiaohong Qiu, Mark A. Tomai, This information is current as Sefik S. Alkan and John P. Vasilakos of September 29, 2021. J Immunol 2005; 174:1259-1268; ; doi: 10.4049/jimmunol.174.3.1259 http://www.jimmunol.org/content/174/3/1259 Downloaded from References This article cites 36 articles, 14 of which you can access for free at: http://www.jimmunol.org/content/174/3/1259.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 29, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2005 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Synthetic TLR Agonists Reveal Functional Differences between Human TLR7 and TLR8 Keith B. Gorden, Kevin S. Gorski, Sheila J. Gibson, Ross M. Kedl,1 William C.
    [Show full text]